Drug Profile

Fibroblast growth factor 1 - Zhittya Genesis Medicine

Alternative Names: FGF-1 - Zhittya Genesis Medicine; Human fibroblast growth factor 1 - Zhittya Genesis Medicine

Latest Information Update: 02 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Zhittya Genesis Medicine
Class Anti-ischaemics; Antidementias; Antidepressants; Antiparkinsonians; Antiulcers; Fibroblast growth factors; Foot disorder therapies; Skin disorder therapies; Vascular disorder therapies
Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Clinical Phase Unknown Parkinson's disease; Type 2 diabetes mellitus
Preclinical Coronary artery disease; COVID 2019 infections; Diabetic foot ulcer; Stroke
Research Vascular dementia
No development reported Alzheimer's disease; Depressive disorders; Leg ulcer; Peripheral arterial disorders

14 May 2026 Fibroblast growth factor 1 is still in preclinical trials for Parkinson's disease, Coronary artery disease, Diabetic foot ulcer, Stroke, Vascular dementia, Alzheimer's disease in the US
08 Dec 2025 Clinical trials in Type 2 diabetes mellitus in USA (Intranasal)
08 Dec 2025 Preclinical trials in Type 2 diabetes mellitus in USA (Intranasal) prior to December 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com